A study has reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma.
Forschungsgruppe Quanteneffekte bei Krankheiten (qrdrg.xonl.de)
Copyright © 2024 MEDIZIN.NEWZS.de - Quantum Related Diseases Research Group (QRDRG)